: Using validated methods from the USP–NF can bring quality therapies to market faster. Global Harmonization
: Contains approximately 5,500 monographs for drug substances and dosage forms (USP) and excipients (NF). Each monograph provides specific requirements for packaging, storage, and labeling, along with validated testing procedures and acceptance criteria.
Standards within USP–NF 47 are legally enforceable by the for medicines manufactured and marketed in the U.S.. Major updates in this edition include: USP-NF 2024 usp nf 47
Several new drug substances and excipients have been added, including novel antiviral agents and specialty excipients used in lipid nanoparticles (the tech behind mRNA vaccines).
Instead, USP transitioned to a years ago. USP–NF 47 refers to the 2024–2025 official text of the compendium, which became official on May 1, 2024 . : Using validated methods from the USP–NF can
USP NF 47 is more than a routine annual update; it brings meaningful changes to chromatographic methods, sterile compounding practices, and numerous monographs. For pharmaceutical manufacturers, the stakes are high: failure to comply can result in FDA 483 observations, warning letters, product recalls, or even seizure.
Standards are updated through a rolling cycle to maintain pace with scientific advancement. Standards within USP–NF 47 are legally enforceable by
While the specific technical changes are vast—spanning hundreds of pages—key trends in this edition often include:
USP moves to a continuous revision model. While USP NF 47 is the official standard now, you should monitor the USP–NF Online platform for and Revision Bulletins . These can become official between annual editions.
If you are referencing a monograph from USP 46 after May 1, 2024, you are out of compliance. Your quality control documentation, specifications, and test methods must reflect USP NF 47.